News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The robotic surgery program has continually pushed the boundaries of medical technology
Becomes the first rehab & recovery center in east India to earn NABH accreditation
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Subscribe To Our Newsletter & Stay Updated
